Clinical Trials

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

Conditions:   Pediatric HIV;   HIV Infections
Intervention:   Drug: Boosted Atazanavir
Sponsors:   Phoenix Children's Hospital;   Bristol-Myers Squibb
Completed

Thu, 16 Jul 2009 12:00:00 EDT

Atazanavir and Endothelial Function in Older HIV Patients

Condition:   HIV
Interventions:   Drug: Atazanavir;   Other: Placebo
Sponsor:   Brigham and Women's Hospital
Completed

Fri, 13 Jan 2017 12:00:00 EST

Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study

Condition:   HIV Infection
Intervention:   Drug: atazanavir 300mg boosted with ritonavir 50 mg
Sponsors:   Ottawa Hospital Research Institute;   Bristol-Myers Squibb
Completed

Tue, 14 Jan 2014 12:00:00 EST

ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir

Condition:   HIV
Intervention:   Drug: Atazanavir
Sponsor:   University of Roma La Sapienza
Unknown status

Wed, 02 Apr 2014 12:00:00 EDT

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

Condition:   HIV
Interventions:   Drug: Atazanavir Sulphate;   Drug: Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 14 Apr 2011 12:00:00 EDT

The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia

Conditions:   Endotoxemia;   Inflammation;   Multi Organ Dysfunction Syndrome;   Sepsis
Interventions:   Drug: Atazanavir;   Drug: E. coli endotoxin
Sponsor:   Radboud University
Completed

Tue, 09 Jun 2009 12:00:00 EDT

Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients

Condition:   HIV Infection
Intervention:   Drug: maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)
Sponsor:   University of Turin, Italy
Withdrawn

Wed, 17 Oct 2018 12:00:00 EDT

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Conditions:   HIV Infection;   Hyperlipidemia
Interventions:   Drug: Atazanavir;   Drug: current antiretroviral regimen
Sponsors:   Northwestern University;   Bristol-Myers Squibb
Completed

Fri, 23 Sep 2005 12:00:00 EDT

Atazanavir/r + Lamivudine Dual Therapy

Condition:   Human Immunodeficiency Virus
Intervention:   Drug: Atazanavir, ritonavir, lamivudine
Sponsor:   Catholic University of the Sacred Heart
Completed

Wed, 16 May 2012 12:00:00 EDT

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

Conditions:   HIV-1 Infection;   Immunosuppression-related Infectious Disease
Interventions:   Drug: DARUNAVIR;   Drug: ATAZANAVIR
Sponsor:   Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Completed

Mon, 26 Aug 2013 12:00:00 EDT

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Condition:   HIV
Interventions:   Drug: Atazanavir (current formulation);   Drug: Atazanavir, powder for oral use 1 (POU1);   Drug: Atazanavir (POU2)
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 28 Jul 2011 12:00:00 EDT

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

Condition:   Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions:   Drug: Atazanavir;   Drug: Cobicistat;   Drug: Atazanavir/Cobicistat FDC
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 23 Apr 2013 12:00:00 EDT

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

Condition:   HIV, Pediatric
Interventions:   Drug: Atazanavir;   Drug: Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 25 Sep 2012 12:00:00 EDT

Raltegravir and Atazanavir Dosing Strategy Study

Condition:   HIV Infection
Intervention:   Drug: atazanavir plus raltegravir
Sponsor:   Kirby Institute
Completed

Thu, 02 Apr 2009 12:00:00 EDT

Atazanavir Twice Daily

Conditions:   HIV Infections;   Protease Inhibitor
Intervention:   Drug: Atazanavir Sulphate
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 27 Jul 2006 12:00:00 EDT

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

Conditions:   HIV Infections;   Protease Inhibitor
Interventions:   Drug: Atazanavir Sulphate + Ritonavir;   Drug: Atazanavir Sulphate + Ritonavir + Efavirenz
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 27 Jul 2006 12:00:00 EDT

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

Conditions:   Hyperlipidemia;   HIV Infections
Intervention:   Drug: Atazanavir
Sponsors:   Stanford University;   Bristol-Myers Squibb
Completed

Mon, 12 Sep 2005 12:00:00 EDT

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)

Condition:   HIV Infections
Interventions:   Drug: Atazanavir powder;   Drug: Ritonavir oral solution;   Drug: Atazanavir capsules;   Drug: Ritonavir capsules
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 07 Apr 2010 12:00:00 EDT

Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction

Condition:   Type 2 Diabetes Mellitus Related Endothelial Dysfunction
Interventions:   Drug: placebo + atazanavir;   Drug: atazanavir + placebo
Sponsors:   Radboud University;   Dutch Diabetes Research Foundation
Completed

Fri, 13 Jun 2008 12:00:00 EDT

Switch to Unboosted Atazanavir With Tenofovir Study

Condition:   HIV Infection
Interventions:   Drug: atazanavir;   Drug: atazanavir/ritonavir
Sponsor:   University of British Columbia
Completed

Wed, 11 May 2011 12:00:00 EDT

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

Condition:   HIV-1 Infection
Intervention:   Drug: Atazanavir/ritonavir monotherapy
Sponsors:   Ospedale San Raffaele;   Bristol-Myers Squibb
Completed

Thu, 19 Jan 2012 12:00:00 EST

Metabolic Effects of Switching Kaletra to Boosted Reyataz

Condition:   HIV Infections
Interventions:   Drug: atazanavir/ritonavir;   Drug: lopinavir/ritonavir
Sponsors:   Massachusetts General Hospital;   Bristol-Myers Squibb
Completed

Tue, 19 Dec 2006 12:00:00 EST

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Condition:   HIV Infection
Interventions:   Drug: atazanavir arm;   Drug: efavirenz
Sponsors:   International Medical Center of Japan;   Ministry of Health, Labour and Welfare, Japan
Completed

Tue, 24 Jan 2006 12:00:00 EST

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients

Condition:   HIV-1 Infection
Intervention:   Drug: Atazanavir 200 mg/r
Sponsors:   Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida;   INSERM UMR S 1136
Completed

Tue, 16 Jun 2015 12:00:00 EDT

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression

Condition:   Human Immunodeficiency Virus (HIV) Infections
Intervention:   Drug: Atazanavir + Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 16 Jun 2006 12:00:00 EDT

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)

Condition:   HIV Infections
Interventions:   Drug: Atazanavir + 2 NRTIs;   Drug: Atazanavir + Ritonavir + 2 NRTIs
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 21 Sep 2005 12:00:00 EDT

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Conditions:   Human Immunodeficiency Virus Type 1 (HIV-1);   HIV Infections
Interventions:   Drug: Voriconazole;   Drug: Atazanavir;   Drug: Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Mon, 02 Feb 2009 12:00:00 EST

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Conditions:   Coronavirus Infection;   Severe Acute Respiratory Infection;   Severe Acute Respiratory Syndrome Coronavirus 2
Interventions:   Drug: Drug: NA-831;   Combination Product: NA-831 and Atazanavir;   Combination Product: NA-831and Dexamethasone;   Combination Product: Atazanavir and Dexamethasone
Sponsor:   NeuroActiva, Inc.
Recruiting

Tue, 30 Jun 2020 12:00:00 EDT

A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia

Condition:   HIV-1 Infection
Intervention:   Drug: atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg
Sponsors:   Castagna Antonella;   Bristol-Myers Squibb;   ViiV Healthcare
Unknown status

Mon, 07 Sep 2015 12:00:00 EDT

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

Conditions:   HIV Infection;   Mitochondrial Dysfunction
Interventions:   Drug: Atazanavir/ritonavir;   Drug: Efavirenz
Sponsors:   The Cleveland Clinic;   National Institute of Allergy and Infectious Diseases (NIAID);   Case Western Reserve University;   Bristol-Myers Squibb
Terminated

Fri, 03 Sep 2010 12:00:00 EDT

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Condition:   HIV
Interventions:   Drug: Lopinavir;   Drug: Atazanavir
Sponsors:   ANRS, Emerging Infectious Diseases;   European and Developing Countries Clinical Trials Partnership (EDCTP);   Ludwig-Maximilians - University of Munich;   Institute of Tropical Medicine, Belgium;   Institut de Recherche pour le Developpement, France;   Swiss National Science Foundation;   University of Limpopo;   NIMR-Mbeya Medical Research Program (MMRP)/ Mbeya Referral Hospital, Tanzania
Withdrawn

Tue, 07 Dec 2010 12:00:00 EST

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

Conditions:   Hepatitis C, Chronic;   HIV Infection
Interventions:   Drug: Ritonavir withdrawal, atazanavir 200 mg/12h;   Drug: Telaprevir interactions
Sponsors:   Hospitales Universitarios Virgen del Rocío;   Bristol-Myers Squibb
Completed

Wed, 27 Mar 2013 12:00:00 EDT

Pharmacokinetics of Atazanavir in Special Populations

Conditions:   HIV/AIDS;   Tuberculosis
Interventions:   Drug: Atazanavir 300mg/ Ritonavir 100 mg once daily;   Drug: Atazanavir 250 mg / ritonavir 80 mg
Sponsors:   University of Liverpool;   Infectious Diseases Institute, Makerere University College of Health Sciences;   Joint Clinical Research Centre- Kampala;   Desmond Tutu HIV Foundation;   University of Cape Town;   European and Developing Countries Clinical Trials Partnership (EDCTP) - funder
Active, not recruiting

Mon, 22 Apr 2019 12:00:00 EDT

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Condition:   HIV Infection
Intervention:   Drug: Atazanavir + Ritonavir + Combivir
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 17 May 2006 12:00:00 EDT

Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine

Condition:   Drug Interaction
Interventions:   Drug: Artemether-lumefantrine;   Drug: Atazanavir-ritonavir 300/100 mg
Sponsors:   Fogarty International Center of the National Institute of Health;   NIH Office of AIDS Research (OAR);   National Institute on Minority Health and Health Disparities (NIMHD);   National Institute of Neurological Disorders and Stroke (NINDS)
Completed

Fri, 28 Aug 2020 12:00:00 EDT

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

Condition:   HIV Infections
Interventions:   Drug: Atazanavir/ Stavidine / Lamivudine;   Drug: Atazanavir-Ritonavir/ Stavidine / Lamivudine
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 11 Jun 2004 12:00:00 EDT

Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients

Condition:   HIV Infections
Interventions:   Drug: Atazanavir (Reyataz);   Drug: Ritonavir (Norvir);   Drug: Nevirapine (Viramune)
Sponsors:   Germans Trias i Pujol Hospital;   Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia;   Hospital San Jaime de Calella
Completed

Tue, 25 Jul 2006 12:00:00 EDT

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Condition:   HIV-1 Infection
Interventions:   Drug: Atazanavir;   Drug: Dolutegravir;   Drug: Lamivudine
Sponsor:   Radboud University
Terminated

Fri, 02 Oct 2015 12:00:00 EDT

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

Conditions:   HIV;   HIV Infections
Intervention:   Drug: darunavir/ritonavir then atazanavir/ritonavir
Sponsor:   St Stephens Aids Trust
Completed

Tue, 23 Feb 2010 12:00:00 EST

Phase IIB Pilot of Atazanavir + Raltegravir

Condition:   HIV
Interventions:   Drug: Atazanavir;   Drug: Raltegravir;   Drug: Ritonavir;   Drug: Tenofovir/Emtricitabine
Sponsors:   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.
Terminated

Wed, 08 Oct 2008 12:00:00 EDT

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

Condition:   Type 1 Diabetes Mellitus
Intervention:   Drug: Atazanavir
Sponsors:   Brigham and Women's Hospital;   National Institutes of Health (NIH)
Completed

Mon, 22 Aug 2011 12:00:00 EDT

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: Reyataz + Norvir + Truvada;   Drug: Reyataz + Epzicom
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed

Tue, 13 Apr 2010 12:00:00 EDT

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

Condition:   HIV Infections
Interventions:   Drug: Atazanavir (immediate switch);   Drug: Atazanavir (Week 24 switch)
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 28 Aug 2003 12:00:00 EDT

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Condition:   HIV Infections
Interventions:   Drug: Truvada;   Drug: Atazanavir;   Drug: Ritonavir
Sponsor:   Gilead Sciences
Completed

Fri, 23 Sep 2005 12:00:00 EDT

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Condition:   HIV
Interventions:   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Tenofovir (TDF);   Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI);   Drug: Famotidine (FAM)
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 02 Nov 2010 12:00:00 EDT

Effect of Atazanavir on Endothelial Function in HIV-Infected Patients

Conditions:   HIV Infections;   Dyslipidemia
Intervention:   Drug: ATAZANAVIR
Sponsors:   Foundation for Cardiovascular Research, Zurich;   Bristol-Myers Squibb
Completed

Wed, 14 Mar 2007 12:00:00 EDT

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

Condition:   HIV Infection
Interventions:   Drug: atazanavir;   Drug: lopinavir/ritonavir
Sponsors:   University of Oklahoma;   Abbott
Terminated

Thu, 11 Jan 2007 12:00:00 EST

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

Condition:   HIV Infections
Interventions:   Drug: Raltegravir and truvada;   Drug: Atazanavir, Norvir and Truvada
Sponsors:   The University of Texas Health Science Center, Houston;   Merck Sharp & Dohme Corp.
Completed

Tue, 30 Sep 2008 12:00:00 EDT

"The Once A Day Protease Inhibitor Regimens"

Condition:   HIV Infections
Interventions:   Drug: ritonavir-boosted atazanavir;   Drug: ritonavir-boosted fosamprenavir
Sponsor:   The University of Texas Health Science Center, Houston
Completed

Wed, 19 Oct 2005 12:00:00 EDT

Genetics and HIV-1 Protease Inhibitors

Condition:   HIV
Intervention:   Drug: Atazanavir
Sponsors:   University of Colorado, Denver;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Wed, 06 Jul 2011 12:00:00 EDT

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Condition:   Healthy Volunteers
Interventions:   Drug: Atazanavir/Cobicistat;   Drug: Atazanavir;   Drug: Cobicistat
Sponsor:   Bristol-Myers Squibb
Not yet recruiting

Mon, 10 Feb 2020 12:00:00 EST

The Nitazoxanide Plus Atazanavir for COVID-19 Study

Condition:   Covid-19
Interventions:   Drug: Nitazoxanide and atazanavir/ritonavir;   Other: Standard of Care
Sponsors:   Obafemi Awolowo University;   University of Liverpool;   African Centre of Excellence for Genomics of Infectious Diseases;   Infectious Disease Hospital Olodo;   Obafemi Awolowo University Teaching Hospitals Complex;   Osun State Ministry of Health;   Olabisi Onabanjo University Teaching Hospital
Recruiting

Tue, 07 Jul 2020 12:00:00 EDT

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

Condition:   Healthy
Interventions:   Drug: Ritonavir-boosted Atazanavir;   Drug: Ritonavir-boosted Atazanavir plus Rabeprazole;   Drug: Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride
Sponsor:   University of California, San Francisco
Completed

Thu, 03 Jan 2013 12:00:00 EST

A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

Condition:   HIV Infections
Intervention:   Drug: Atazanavir
Sponsor:   Bristol-Myers Squibb
Terminated

Tue, 11 Apr 2006 12:00:00 EDT

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Condition:   HIV, Combination Therapy
Interventions:   Drug: Atazanavir;   Drug: Ritonavir (heat-stable);   Drug: Raltegravir;   Drug: Tenofovir/Emtricitabine
Sponsor:   Bristol-Myers Squibb
Completed

Mon, 11 Apr 2011 12:00:00 EDT

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

Condition:   HIV-Associated Lipodystrophy Syndrome
Interventions:   Drug: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs);   Drug: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 26 Aug 2005 12:00:00 EDT

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

Conditions:   Infection, Human Immunodeficiency Virus I;   HIV Infection
Interventions:   Drug: Trizivir;   Drug: atazanavir;   Drug: Combivir
Sponsor:   GlaxoSmithKline
Completed

Mon, 10 May 2004 12:00:00 EDT

Taste Properties of Atazanavir and Cobicistat

Condition:   HIV in Adults
Interventions:   Drug: Atazanavir;   Drug: Cobicistat;   Drug: Active Pharmaceutical Ingredient
Sponsor:   Bristol-Myers Squibb
Unknown status

Thu, 04 Dec 2014 12:00:00 EST

Atazanavir and Lamivudine for Treatment Simplification

Condition:   HIV Infections
Interventions:   Drug: Lamiduvine (Epivir);   Drug: Atazanavir (Reyataz);   Drug: Ritonavir (Norvir)
Sponsor:   Catholic University of the Sacred Heart
Completed

Wed, 22 Apr 2009 12:00:00 EDT

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Boosted atazanavir;   Drug: Lamivudine
Sponsors:   David Garcia Cinca;   Fundacion Clinic per a la Recerca Biomédica
Unknown status

Tue, 12 Jan 2016 12:00:00 EST

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

Condition:   Healthy Volunteer
Interventions:   Drug: GSK1349572;   Drug: Atazanavir 300 mg;   Drug: Atazanavir 400 mg;   Drug: Ritonavir
Sponsors:   GlaxoSmithKline;   Shionogi
Completed

Mon, 20 Apr 2009 12:00:00 EDT

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Conditions:   HIV Infection;   Osteopenia
Interventions:   Drug: raltegravir and atazanavir and ritonavir;   Drug: tenofovir/emtricitabine and atazanavir and ritonavir
Sponsors:   Giovanni Di Perri;   University of Turin, Italy;   University of Milan
Terminated

Thu, 18 Jul 2013 12:00:00 EDT

SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat

Condition:   HIV
Interventions:   Drug: Evotaz;   Drug: Rezolsta
Sponsors:   St Stephens Aids Trust;   Bristol-Myers Squibb
Completed

Wed, 28 Oct 2015 12:00:00 EDT

Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients

Condition:   HIV Infections
Intervention:   Drug: Atazanavir
Sponsors:   The HIV Netherlands Australia Thailand Research Collaboration;   Bristol-Myers Squibb
Completed

Fri, 15 Dec 2006 12:00:00 EST

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Conditions:   Solid Tumor;   Hematological Malignancies
Interventions:   Drug: Belinostat;   Drug: Atazanavir
Sponsors:   Acrotech Biopharma LLC;   Axis Clinicals Limited
Recruiting

Wed, 04 Dec 2019 12:00:00 EST

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Conditions:   Hepatitis C;   HIV
Interventions:   Drug: Daclatasvir;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Cobicistat
Sponsor:   Radboud University
Completed

Thu, 01 Oct 2015 12:00:00 EDT

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

Condition:   HIV Infections
Interventions:   Drug: Atazanavir + ritonavir + tenofovir + nucleoside;   Drug: Atazanavir + saquinavir + tenofovir + nucleoside;   Drug: Lopinavir/ritonavir + tenofovir + nucleoside
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 08 May 2002 12:00:00 EDT

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

Condition:   HIV Infections
Intervention:   Drug: Raltegravir and Atazanavir
Sponsor:   Peter J. Ruane, M.D., Inc.
Unknown status

Thu, 11 Sep 2008 12:00:00 EDT

Drug Interaction Study

Condition:   Antivirals/HIV
Interventions:   Drug: Rifabutin;   Drug: Rifabutin + Atazanavir + Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Mon, 31 Mar 2008 12:00:00 EDT

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Condition:   HIV Infections
Interventions:   Drug: ATV/r;   Drug: DRV/r
Sponsors:   Community Research Initiative of New England;   Tibotec Pharmaceutical Limited
Completed

Mon, 22 Sep 2008 12:00:00 EDT

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Condition:   HIV Infection
Interventions:   Drug: Ritonavir boosted Atazanavir + Lamivudine;   Drug: Ritonavir boosted Atazanavir + 2 NRTIs
Sponsors:   Fundacion SEIMC-GESIDA;   Bristol-Myers Squibb
Completed

Thu, 03 Mar 2011 12:00:00 EST

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Condition:   HIV Infections
Interventions:   Drug: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate);   Drug: Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 27 Jul 2006 12:00:00 EDT

DDI HV (ATV - Merck)

Condition:   HIV Infections
Interventions:   Drug: Raltegravir;   Drug: Atazanavir;   Drug: Atazanavir + Raltegravir
Sponsors:   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.
Completed

Mon, 20 Aug 2007 12:00:00 EDT

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

Condition:   HIV Infections
Interventions:   Drug: atazanavir/ritonavir +2 NRTIs (immediate Switch Group);   Drug: LPV/r +2 NRTIs (Delayed/optional Switch Group)
Sponsor:   Bristol-Myers Squibb
Completed

Mon, 18 Jul 2005 12:00:00 EDT

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Conditions:   HIV Infections;   Hepatitis C
Interventions:   Drug: Raltegravir;   Drug: Atazanavir/Ritonavir
Sponsor:   St. James's Hospital, Ireland
Unknown status

Fri, 16 Apr 2010 12:00:00 EDT

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Condition:   HIV Infections
Interventions:   Drug: ATV;   Drug: RTV;   Drug: Tenofovi-Emtricitabine (TDF/FTC) tablet;   Drug: LPV
Sponsor:   Bristol-Myers Squibb
Completed

Mon, 09 Jan 2006 12:00:00 EST

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

Condition:   HIV Infections
Interventions:   Drug: nevirapine bid;   Drug: nevirapine qd;   Drug: atazanavir
Sponsor:   Boehringer Ingelheim
Completed

Wed, 18 Oct 2006 12:00:00 EDT

Bioequivalence Study of Atazanavir 300 mg Capsule

Condition:   HIV Infections
Intervention:   Drug: Atazanavir + Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 27 Oct 2006 12:00:00 EDT

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

Conditions:   HIV Infection;   HIV Infections
Interventions:   Drug: raltegravir QD;   Drug: atazanavir;   Drug: lamivudine (or emtricitabine)
Sponsor:   Radboud University
Completed

Wed, 22 Jul 2009 12:00:00 EDT

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Condition:   HIV
Interventions:   Drug: atazanavir/raltegravir;   Drug: atazanavir/tenofovir/emtricitabine
Sponsors:   Community Research Initiative of New England;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.
Completed

Thu, 02 Jul 2009 12:00:00 EDT

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Condition:   Endothelial Dysfunction
Interventions:   Drug: Atazanavir;   Drug: Lopinavir/ritonavir;   Drug: Placebo
Sponsors:   Indiana University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed

Wed, 23 Jul 2008 12:00:00 EDT

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Nelfinavir mesylate
Sponsor:   Bristol-Myers Squibb
Terminated

Tue, 11 Dec 2001 12:00:00 EST

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

Condition:   HIV
Interventions:   Drug: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir;   Drug: Ritonavir, Atazanavir, Truvada
Sponsors:   Kenneth H. Mayer, MD;   Bristol-Myers Squibb;   Gilead Sciences;   Abbott
Terminated

Mon, 21 May 2012 12:00:00 EDT

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

Condition:   HIV Infections
Interventions:   Drug: Atazanavir+ritonavir;   Drug: Lopinavir+ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 26 Aug 2005 12:00:00 EDT

Atazanavir/Ritonavir Maintenance Therapy

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Ritonavir
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Mon, 07 Jun 2004 12:00:00 EDT

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition:   Human Immunodeficiency Virus-1
Intervention:   Drug: maraviroc
Sponsors:   ViiV Healthcare;   Pfizer
Completed

Thu, 22 Jan 2009 12:00:00 EST

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

Condition:   HIV Infections
Interventions:   Drug: Rosiglitazone maleate;   Drug: Atazanavir Sulphate;   Drug: Atazanavir Sulphate + Rosiglitazone maleate;   Drug: Atazanavir Sulphate + Ritonavir;   Drug: Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 10 Aug 2006 12:00:00 EDT

Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers

Condition:   Atazanavir
Interventions:   Drug: atazanavir;   Drug: Atazanavir(ATZ) and Tenofovir(TDF);   Drug: Atazanavir(ATZ) + Ritonavir;   Drug: atazanavir(ATZ) + tenofovir(TDF) + ritonavir
Sponsors:   Asan Medical Center;   Bristol-Myers Squibb
Unknown status

Wed, 08 Jun 2011 12:00:00 EDT

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

Conditions:   Infection, Human Immunodeficiency Virus I;   HIV Infection
Interventions:   Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r);   Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed

Tue, 27 Feb 2007 12:00:00 EST

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Conditions:   HIV;   Hepatitis C
Interventions:   Drug: raltegravir;   Drug: Atazanavir/ritonavir
Sponsors:   University Hospital, Bonn;   Dr. Axel Baumgarten, Berlin;   Dr. Christoph Stephan, Frankfurt/M;   Dr. Stefan Esser, Essen;   Dr. Keikawus Arastéh, Berlin;   Prof. Dr. Hans-Jürgen Stellbrink, Hamburg;   Dr. Thomas Lutz, Frankfurt/M;   Dr. Jörg Gölz , Berlin
Withdrawn

Thu, 21 Oct 2010 12:00:00 EDT

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Condition:   HIV
Interventions:   Drug: Atazanavir;   Drug: Atazanavir/Ritonavir;   Drug: Tenofovir/Emtricitabine;   Drug: Lopinavir/ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 29 Oct 2009 12:00:00 EDT

Atazanavir for HIV Infected Individuals: An Early Access Program

Condition:   HIV Infections
Intervention:   Drug: Atazanavir (BMS-232632)
Sponsor:   Bristol-Myers Squibb
No longer available

Mon, 30 Sep 2002 12:00:00 EDT

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

Condition:   HIV Infections
Intervention:   Drug: Atazanvir/ritonavir + efavirenz
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 26 Aug 2005 12:00:00 EDT

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients

Condition:   Chronic Infection With HIV
Interventions:   Drug: Ritonavir boosted Atazanavir;   Drug: Raltegravir;   Drug: TDF/FTC (or 3TC)
Sponsors:   Pedro Cahn;   Merck Sharp & Dohme Corp.
Unknown status

Thu, 11 Apr 2013 12:00:00 EDT

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Lopinavir/Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 21 Dec 2001 12:00:00 EST

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Condition:   HIV
Interventions:   Drug: ritonavir;   Drug: darunavir;   Drug: emtricitabine [FTC]/tenofovir [TDF];   Drug: atazanavir
Sponsors:   Tibotec, Inc;   Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Completed

Tue, 23 Sep 2008 12:00:00 EDT

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

Condition:   HIV Infections
Interventions:   Drug: lamivudine, abacavir , ritonavir, atazanavir;   Drug: emtricitabine, tenofovir, ritonavir, atazanavir
Sponsors:   International Medical Center of Japan;   Ministry of Health, Labour and Welfare, Japan
Completed

Tue, 16 Oct 2007 12:00:00 EDT

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

Condition:   HIV Infections
Interventions:   Drug: saquinavir/ritonavir;   Drug: atazanavir/ritonavir
Sponsors:   International Antiviral Therapy Evaluation Center;   Hoffmann-La Roche;   Gilead Sciences
Completed

Wed, 18 Oct 2006 12:00:00 EDT

Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

Condition:   Healthy Volunteers
Interventions:   Drug: C-10276;   Drug: C-10297;   Drug: C-10299;   Drug: Reyataz®
Sponsor:   Concert Pharmaceuticals
Completed

Tue, 25 Oct 2011 12:00:00 EDT

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Conditions:   Acquired Immune Deficiency Syndrome;   AIDS;   Human Immunodeficiency Virus;   HIV Infections
Interventions:   Drug: Raltegravir;   Drug: Atazanavir;   Other: Standard treatment regimen
Sponsors:   Yale University;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.
Completed

Thu, 25 Dec 2008 12:00:00 EST

ATV/Ritonavir Nevirapine Interaction (USPAC)

Condition:   HIV Infections
Interventions:   Drug: Nevirapine;   Drug: Nevirapine + Atazanavir/Ritonavir;   Drug: Atazanavir + Ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 13 Sep 2005 12:00:00 EDT

Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis

Condition:   HIV Infections
Interventions:   Drug: Combivir+Kaletra;   Drug: Combivir+Reyataz
Sponsor:   Hospital Clinic of Barcelona
Completed

Wed, 11 Oct 2006 12:00:00 EDT

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Tenofovir/emtricitabine
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   Bristol-Myers Squibb;   Gilead Sciences
Completed

Tue, 11 Sep 2007 12:00:00 EDT

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Conditions:   HIV;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions:   Drug: TAF;   Drug: Placebo;   Drug: E/C/F/TAF;   Drug: Current failing ARV regimen;   Drug: ATV
Sponsor:   Gilead Sciences
Completed

Wed, 23 Oct 2013 12:00:00 EDT

Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

Condition:   Healthy
Interventions:   Drug: Tipranavir;   Drug: Ritonavir;   Drug: Atazanavir
Sponsor:   Boehringer Ingelheim
Completed

Wed, 01 Oct 2014 12:00:00 EDT

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

Condition:   HIV Infections
Interventions:   Drug: tenofovir DF 300 mg QD;   Drug: emtricitabine 200 mg QD;   Drug: Nevirapine 200 mg BID;   Drug: Atazanavir 300 mg;   Drug: Ritonavir 100 mg
Sponsor:   Boehringer Ingelheim
Completed

Thu, 01 Nov 2007 12:00:00 EDT

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

Conditions:   HIV Infections;   Tuberculosis
Interventions:   Drug: Atazanavir;   Drug: Rifampin;   Drug: Ritonavir
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   AIDS Clinical Trials Group
Completed

Wed, 17 Nov 2004 12:00:00 EST

Atazavanir/Ritonavir-based HAART in Children

Condition:   HIV
Intervention:   Drug: boosted atazanavir (ATV/r)
Sponsors:   The HIV Netherlands Australia Thailand Research Collaboration;   amfAR, The Foundation for AIDS Research;   National Health Security Office, Thailand;   The Thai Government Pharmaceutical Organization (GPO)
Completed

Thu, 02 Aug 2012 12:00:00 EDT

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Saquinavir
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 31 Aug 2001 12:00:00 EDT

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV);   Drug: tenofovir/emtricitabine (TDF/FTC);   Drug: Atazanavir (ATV);   Drug: Ritonavir;   Procedure: Phlebotomy
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Wed, 11 Aug 2010 12:00:00 EDT

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

Condition:   HIV Infections
Interventions:   Drug: Atazanavir/Ritonavir;   Drug: Atazanavir/Ritonavir + Famotidine;   Drug: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 06 Oct 2006 12:00:00 EDT

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Lamivudine/Zidovudine;   Drug: Efavirenz
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 31 Aug 2001 12:00:00 EDT

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Condition:   Healthy Volunteer
Interventions:   Drug: atazanavir;   Drug: danoprevir;   Drug: ritonavir;   Drug: tenofovir disoproxil fumarate
Sponsor:   Hoffmann-La Roche
Completed

Mon, 07 May 2012 12:00:00 EDT

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Conditions:   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions:   Drug: Atazanavir (ATV) 300 mg;   Drug: Atazanavir (ATV) 400 mg;   Drug: Ritonavir (rtv) 100 mg;   Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs);   Drug: Etravirine (ETR) 200 mg;   Drug: Tenofovir disoproxil fumarate (TDF) 300 mg
Sponsor:   Janssen R&D Ireland
Completed

Mon, 11 May 2009 12:00:00 EDT

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

Condition:   HIV-1
Interventions:   Drug: Darunavir / Ritonavir + Tenofovir / Emtricitabine;   Drug: Atazanavir / Ritonavir + Tenofovir / Emtricitabine
Sponsor:   Juan A. Arnaiz
Completed

Wed, 12 Jan 2011 12:00:00 EST

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Condition:   HIV
Interventions:   Drug: Atazanavir;   Drug: Darunavir;   Drug: Ritonavir;   Drug: Optimized NRTI backbone
Sponsor:   Bristol-Myers Squibb
Withdrawn

Thu, 24 May 2012 12:00:00 EDT

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Conditions:   HIV;   HIV Infections
Interventions:   Drug: COBI;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI placebo;   Drug: RTV placebo
Sponsor:   Gilead Sciences
Completed

Thu, 22 Apr 2010 12:00:00 EDT

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Condition:   HIV-1 Infection
Interventions:   Drug: COBI;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI placebo;   Drug: RTV placebo
Sponsor:   Gilead Sciences
Completed

Mon, 04 May 2009 12:00:00 EDT

Korean Post-marketing Surveillance for Reyataz®

Condition:   HIV-1
Intervention:   Drug: No Intervention
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 12 Oct 2011 12:00:00 EDT

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Nelfinavir mesylate;   Drug: Stavudine;   Drug: Didanosine
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 31 Aug 2001 12:00:00 EDT

The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects

Condition:   HIV Infections
Interventions:   Drug: nevirapine;   Drug: atazanavir/ritonavir
Sponsors:   Imperial College London;   Boehringer Ingelheim
Completed

Fri, 05 Oct 2007 12:00:00 EDT

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Condition:   HIV Infections
Interventions:   Drug: Atazanavir+Ritonavir+Tenofovir;   Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 17 Aug 2006 12:00:00 EDT

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

Condition:   Healthy Volunteer
Interventions:   Drug: RO5093151;   Drug: atazanavir;   Drug: ketoconazole;   Drug: rifampicin;   Drug: ritonavir
Sponsor:   Hoffmann-La Roche
Completed

Fri, 04 May 2012 12:00:00 EDT

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

Conditions:   HIV;   Impaired Cognition
Interventions:   Drug: standard care;   Drug: novel treatment
Sponsors:   Imperial College London;   Pfizer
Completed

Tue, 07 Jun 2011 12:00:00 EDT

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

Condition:   HIV Infected
Intervention:   Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Sponsors:   University of Alabama at Birmingham;   National Institute of Allergy and Infectious Diseases (NIAID)
Withdrawn

Thu, 14 Jul 2011 12:00:00 EDT

Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir

Conditions:   HIV;   Dyslipidemia
Interventions:   Drug: pitavastatin;   Drug: placebo
Sponsor:   Ramathibodi Hospital
Completed

Wed, 13 May 2015 12:00:00 EDT

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Condition:   HIV Infection
Intervention:  
Sponsors:   Bristol-Myers Squibb;   PENTA Foundation
Completed

Fri, 08 Jul 2011 12:00:00 EDT

HIV Antiretroviral Drugs and Metabolism

Condition:   HIV Infections
Intervention:   Drug: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Unknown status

Wed, 05 Sep 2007 12:00:00 EDT

Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants

Conditions:   Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Interventions:   Drug: ATV;   Drug: DRV;   Drug: Cobicistat;   Drug: BR
Sponsor:   Gilead Sciences
Recruiting

Fri, 20 Dec 2013 12:00:00 EST

A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study

Condition:   HIV Infections
Interventions:   Drug: saquinavir 500 formulation;   Drug: cross-over arm
Sponsors:   Kirby Institute;   Hoffmann-La Roche
Completed

Mon, 19 Sep 2005 12:00:00 EDT

Drug Interaction Study With Proton Pump Inhibitor

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Atazanavir/Ritonavir;   Drug: Atazanavir/Ritonavir+Omeprazole
Sponsor:   Bristol-Myers Squibb
Completed

Thu, 27 Jul 2006 12:00:00 EDT

Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir

Condition:   HIV/AIDS
Intervention:  
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 26 Aug 2015 12:00:00 EDT

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

Condition:   HIV Infections
Intervention:   Drug: Atazanavir/Ritonavir/Lopinavir/ritonavir
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 26 Aug 2005 12:00:00 EDT

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Condition:   HIV Infections
Interventions:   Drug: Abacavir/Lamivudine;   Drug: Atazanavir;   Drug: Efavirenz;   Drug: Emtricitabine/Tenofovir disoproxil fumarate;   Drug: Ritonavir;   Drug: Abacavir/Lamivudine placebo;   Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Tue, 12 Jul 2005 12:00:00 EDT

Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia

Condition:   HIV
Intervention:  
Sponsors:   Holdsworth House Medical Practice;   Bristol-Myers Squibb
Completed

Thu, 12 Sep 2013 12:00:00 EDT

Antiviral Agents Against COVID-19 Infection

Condition:   COVID-19
Interventions:   Drug: Atazanavir;   Drug: Daclatasvir 60 mg;   Drug: Sofusbuvir + Daclastavir 60 mg;   Drug: Placebo Atazanavir;   Drug: Placebo Daclatasvir 60 mg;   Drug: Placebo Sofusbuvir + Daclatasvir 60 mg
Sponsor:   Hospital do Coracao
Recruiting

Mon, 13 Jul 2020 12:00:00 EDT

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS

Condition:   HIV/AIDS
Interventions:   Drug: Darunavir;   Drug: ART with 2 NRTIs plus LPV/r (or ATV/r)
Sponsors:   University of Liverpool;   Janssen Pharmaceutica;   Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS;   Yaounde Central Hospital
Completed

Wed, 04 Jun 2014 12:00:00 EDT

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

Condition:   HIV Infections
Interventions:   Procedure: Early Initiation of Highly Active Anti-Retroviral Therapy;   Procedure: Standard Care
Sponsors:   University of North Carolina, Chapel Hill;   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH);   International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Completed

Tue, 26 Jun 2007 12:00:00 EDT

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Conditions:   Infection, Human Immunodeficiency Virus;   HIV Infections
Interventions:   Drug: Dolutegravir/abacavir/lamivudine FDC;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Tenofovir/emtricitabine FDC
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Active, not recruiting

Mon, 29 Jul 2013 12:00:00 EDT

Evaluation of Atazanavir Substitution Intervention (EASI) Study

Condition:   HIV Infections
Intervention:  
Sponsor:   University of British Columbia
Completed

Wed, 02 Nov 2005 12:00:00 EST

ANRS 12372 MODERATO Study

Condition:   HIV-1-infection
Interventions:   Drug: dolutegravir;   Drug: atazanavir boosted with ritonavir;   Drug: tenofovir + lamivudine +efavirenz;   Drug: Lamivudine
Sponsors:   ANRS, Emerging Infectious Diseases;   Mylan Laboratories
Recruiting

Wed, 17 Jul 2019 12:00:00 EDT

Pharmacokinetic Effect of Evotaz/Microgynon Co-administration

Condition:   HIV
Interventions:   Drug: Microgynon 30®;   Drug: Evotaz®
Sponsors:   St Stephens Aids Trust;   Bristol-Myers Squibb
Terminated

Thu, 03 Mar 2016 12:00:00 EST

Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Condition:   HIV Infections
Intervention:   Drug: ATV/r
Sponsors:   The HIV Netherlands Australia Thailand Research Collaboration;   Kirby Institute;   National Health Security Office, Thailand
Completed

Fri, 09 Jul 2010 12:00:00 EDT

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Condition:   HIV-1 Infection
Interventions:   Drug: RTV;   Drug: ATV;   Drug: DRV;   Drug: COBI;   Drug: ATV/co;   Drug: DRV/co;   Drug: FTC/TDF;   Drug: ABC/3TC;   Drug: B/F/TAF
Sponsor:   Gilead Sciences
Completed

Wed, 11 Nov 2015 12:00:00 EST

A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)

Condition:   HIV
Interventions:   Drug: Lopinavir ritonavir;   Drug: Atazanavir ritonavir;   Drug: Efavirenz
Sponsor:   Göteborg University
Completed

Mon, 03 Oct 2011 12:00:00 EDT

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Conditions:   Infection, Human Immunodeficiency Virus;   HIV Infections
Interventions:   Drug: BMS-955176;   Drug: Placebo matching with BMS-955176;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Tenofovir;   Drug: Emtricitabine
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed

Mon, 04 Mar 2013 12:00:00 EST

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

Conditions:   Pregnancy;   HIV;   AIDS
Intervention:   Drug: Norethindrone acetate
Sponsors:   University of Southern California;   Society of Family Planning
Completed

Fri, 17 Aug 2012 12:00:00 EDT

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Condition:   HIV Infections
Interventions:   Drug: BMS-955176;   Drug: Atazanavir (ATV);   Drug: Ritonavir (RTV);   Drug: Dolutegravir (DTG);   Drug: Tenofovir (TDF)
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Terminated

Wed, 11 Mar 2015 12:00:00 EDT

Atazanavir/Ritonavir and Zinc Pharmacokinetic Study

Condition:   HIV Infection
Interventions:   Drug: 1 Solvazinc tablet, day 2 to day 15;   Drug: 1 Solvazinc tablet, day 15 to day 28
Sponsor:   St Stephens Aids Trust
Completed

Mon, 21 Nov 2011 12:00:00 EST

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

Condition:   HIV Infections
Intervention:   Drug: Addition of raltegravir 800 mg QD to HAART
Sponsors:   Germans Trias i Pujol Hospital;   Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Completed

Fri, 18 Jul 2008 12:00:00 EDT

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Condition:   HIV-1 Infection
Interventions:   Drug: STB;   Drug: TVD;   Drug: ATR;   Drug: RTV;   Drug: ATV;   Drug: ABC/3TC;   Drug: Iohexol
Sponsor:   Gilead Sciences
Completed

Tue, 23 Sep 2014 12:00:00 EDT

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

Condition:   HIV Infections
Intervention:   Procedure: blood draw
Sponsors:   University of North Carolina, Chapel Hill;   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH);   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed

Mon, 09 Jan 2006 12:00:00 EST

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Condition:   Healthy
Interventions:   Drug: tenofovir;   Drug: emtricitabine;   Drug: atazanavir;   Drug: ritonavir
Sponsors:   University of Alabama at Birmingham;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Thu, 26 Mar 2009 12:00:00 EDT

Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults

Condition:   HIV Infections
Intervention:   Drug: Structured treatment interruption
Sponsor:   ANRS, Emerging Infectious Diseases
Completed

Fri, 09 Jan 2009 12:00:00 EST

Disulfiram Interactions With HIV Medications: Clinical Implications

Conditions:   HIV Infections;   Drug Abuse
Interventions:   Drug: Disulfiram;   Drug: Disulfiram + Efavirenz;   Drug: Disulfiram + Atazanavir;   Drug: Disulfiram + Ritonavir
Sponsors:   University of California, San Francisco;   National Institute on Drug Abuse (NIDA)
Completed

Wed, 08 Apr 2009 12:00:00 EDT

Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition:   HIV Infection
Interventions:   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Raltegravir;   Drug: Darunavir;   Drug: Ritonavir;   Drug: Atazanavir
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Bristol-Myers Squibb;   Gilead Sciences;   Merck Sharp & Dohme Corp.;   Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Completed

Fri, 19 Dec 2008 12:00:00 EST

Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)

Condition:   HIV Infections
Intervention:  
Sponsors:   The HIV Netherlands Australia Thailand Research Collaboration;   Chulalongkorn University;   Kirby Institute;   Radboud University;   South East Asia Research Collaboration with Hawaii
Completed

Mon, 07 Jun 2010 12:00:00 EDT

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Conditions:   HIV;   HIV Infections
Interventions:   Drug: Stribild;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: Stribild Placebo;   Drug: ATV Placebo;   Drug: RTV Placebo;   Drug: FTC/TDF Placebo
Sponsor:   Gilead Sciences
Completed

Tue, 20 Apr 2010 12:00:00 EDT

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

Condition:   HIV-1
Interventions:   Drug: Dolutegravir;   Drug: PI;   Drug: 2 NRTI
Sponsors:   Hospital Universitari Vall d'Hebron Research Institute;   University Hospital, Ghent;   IrsiCaixa
Completed

Fri, 31 Jul 2015 12:00:00 EDT

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Condition:   HIV Infection
Interventions:   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Ritonavir;   Drug: Atazanavir;   Drug: Raltegravir;   Drug: Darunavir
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Thu, 26 Feb 2009 12:00:00 EST

Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load

Conditions:   HIV/AIDS;   Tuberculosis
Intervention:   Drug: Dose escalation
Sponsors:   University of Liverpool;   European and Developing Countries Clinical Trials Partnership (Funder);   Joint Clinical Research Centre, Kampala, Uganda;   University of Cape Town, Cape Town, South Africa;   Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda;   University of Turin, Turin, Italy
Recruiting

Wed, 09 Oct 2019 12:00:00 EDT

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

Condition:   HIV Infection
Intervention:   Drug: LPV/RTV + 2NRTIs
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 16 Nov 2004 12:00:00 EST

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Condition:   HIV
Intervention:  
Sponsors:   Bristol-Myers Squibb;   PharmaNet
Completed

Sun, 07 Nov 2010 12:00:00 EDT

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Condition:   HIV Infections
Interventions:   Drug: ATV;   Drug: Ritonavir
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Completed

Fri, 31 Aug 2001 12:00:00 EDT

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl

Condition:   HIV Infections
Interventions:   Drug: tenofovir + emtricitabine + efavirenz;   Drug: tenofovir + emtricitabine + lopinavir-ritonavir;   Drug: tenofovir + emtricitabine + atazanavir-ritonavir
Sponsor:   Juan A. Arnaiz
Completed

Thu, 20 Sep 2007 12:00:00 EDT

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Stavudine;   Drug: Didanosine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Bristol-Myers Squibb
Completed

Fri, 31 Aug 2001 12:00:00 EDT

PK TDF in Thai HIV-infected Children

Condition:   HIV
Interventions:   Drug: TDF (Tenofovir);   Drug: Efavirenz;   Drug: lopinavir/ritonavir, atazanavir/ritonavir
Sponsors:   The HIV Netherlands Australia Thailand Research Collaboration;   Chulalongkorn University;   Khon Kaen University
Completed

Tue, 31 Mar 2015 12:00:00 EDT

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz);   Drug: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV);   Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
Sponsors:   Kirby Institute;   The University of New South Wales
Completed

Fri, 09 Jun 2006 12:00:00 EDT

Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers

Condition:   Healthy
Interventions:   Drug: BILR 355 BS;   Other: Grapefruit juice;   Drug: Nelfinavir;   Drug: Atazanavir;   Drug: Ritonavir
Sponsor:   Boehringer Ingelheim
Completed

Mon, 06 Oct 2014 12:00:00 EDT

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

Condition:   HIV Infections
Interventions:   Drug: Vicriviroc;   Drug: emtricitabine and tenofovir disoproxil fumarate
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Tue, 30 Oct 2007 12:00:00 EDT

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects

Condition:   HIV Infection
Intervention:   Drug: Aprepitant
Sponsor:   University of Pennsylvania
Completed

Tue, 03 Jun 2014 12:00:00 EDT

Clinical Trial of CNS-targeted HAART (CIT2)

Condition:   HIV Infections
Intervention:   Drug: FDA Approved Antiretroviral Therapy (see list below)
Sponsors:   University of California, San Diego;   National Institutes of Health (NIH);   National Institute of Mental Health (NIMH)
Completed

Wed, 27 Feb 2008 12:00:00 EST

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: E/C/F/TDF;   Drug: ATV;   Drug: RTV;   Drug: FTC/TDF;   Drug: E/C/F/TDF Placebo;   Drug: ATV Placebo;   Drug: RTV Placebo;   Drug: FTC/TDF Placebo;   Drug: E/C/F/TAF
Sponsor:   Gilead Sciences
Completed

Fri, 12 Oct 2012 12:00:00 EDT

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Condition:   HIV Infections
Interventions:   Drug: Nevirapine;   Drug: Efavirenz;   Drug: Indinavir/ritonavir;   Drug: Nelfinavir;   Drug: Saquinavir/ritonavir;   Drug: Lopinavir/ritonavir;   Drug: Atazanavir;   Drug: Atazanavir/ritonavir;   Drug: Fos-amprenavir/ritonavir;   Drug: Tipranavir/ ritonavir;   Drug: Darunavir/ritonavir
Sponsors:   Germans Trias i Pujol Hospital;   Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Completed

Tue, 28 Mar 2006 12:00:00 EST

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Condition:   HIV-1 Infection
Interventions:   Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: ATV;   Drug: RTV;   Drug: FTC/TDF;   Drug: B/F/TAF
Sponsor:   Gilead Sciences
Completed

Tue, 12 Jan 2016 12:00:00 EST

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

Conditions:   Women's Health;   HIV Infection;   Genital Diseases, Female
Intervention:  
Sponsor:   University of Colorado, Denver
Completed

Fri, 21 Oct 2011 12:00:00 EDT

Population Pharmacokinetics of Antiretroviral in Children

Condition:   Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed
Interventions:   Biological: Dolutegravir;   Biological: Raltegravir;   Biological: Rilpivirine;   Biological: Nevirapine;   Biological: Atazanavir;   Biological: Darunavir;   Biological: Ritonavir
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting

Wed, 21 Jun 2017 12:00:00 EDT

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Condition:   HIV
Interventions:   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Lamivudine;   Drug: Tenofovir/Emtricitabine
Sponsor:   Bristol-Myers Squibb
Terminated

Fri, 15 Jun 2012 12:00:00 EDT

Antiretroviral Drug Interaction Study in Volunteers With HIV

Conditions:   HIV;   PCP;   Toxoplasmosis
Interventions:   Drug: Atovaquone 750 mg twice daily;   Drug: Atovaquone 1500 mg twice daily
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed

Thu, 24 Nov 2011 12:00:00 EST

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Condition:   HIV Infections
Interventions:   Drug: Raltegravir (MK-0518);   Drug: Nevirapine;   Drug: Lamivudine;   Drug: Tenofovir;   Drug: Emtricitabine;   Drug: Lopinavir;   Drug: Ritonavir;   Drug: Atazanavir;   Drug: Darunavir
Sponsor:   Merck Sharp & Dohme Corp.
Terminated

Thu, 17 Apr 2014 12:00:00 EDT

Unboosted Atazanavir as Initial ART Therapy in China

Condition:   Antiretroviral Therapy
Intervention:  
Sponsors:   National Center for AIDS/STD Control and Prevention, China CDC;   BMS company
Completed

Tue, 25 Oct 2011 12:00:00 EDT

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

Conditions:   HIV Infections;   Lipodystrophy;   Wasting Disease
Interventions:   Drug: Abacavir sulfate;   Drug: Atazanavir/Ritonavir;   Drug: Lopinavir/Ritonavir;   Drug: Nevirapine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Fri, 21 Dec 2001 12:00:00 EST

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition:   HIV Infections
Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Completed

Thu, 01 Aug 2002 12:00:00 EDT

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: E/C/F/TDF;   Drug: COBI;   Drug: ATV;   Drug: DRV;   Drug: NRTI
Sponsor:   Gilead Sciences
Completed

Wed, 01 Jun 2011 12:00:00 EDT

Sex, Aging and Antiretroviral Pharmacokinetics

Condition:   HIV Infections
Intervention:   Drug: ARV regimen chosen by treating physician
Sponsors:   Kristine Patterson, MD;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Thu, 24 Apr 2008 12:00:00 EDT

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Didanosine (enteric-coated);   Drug: Efavirenz;   Drug: Emtricitabine;   Drug: Emtricitabine/Tenofovir disoproxil fumarate;   Drug: Lamivudine/Zidovudine
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Tue, 08 Jun 2004 12:00:00 EDT

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

Condition:   HIV Infections
Interventions:   Drug: raltegravir;   Drug: Study NNRTI;   Drug: Study PI
Sponsor:   University of California, San Francisco
Completed

Tue, 21 Apr 2009 12:00:00 EDT

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Conditions:   Hepatitis C;   HIV
Interventions:   Drug: SOF;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
Sponsor:   Gilead Sciences
Completed

Thu, 29 Mar 2012 12:00:00 EDT

Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy

Conditions:   Ebola;   HIV/AIDS
Intervention:   Drug: Remdesivir
Sponsors:   Makerere University;   University of Liverpool;   European and Developing Countries Clinical Trials Partnership (EDCTP);   University of Turin, Italy
Completed

Wed, 13 May 2020 12:00:00 EDT

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

Condition:   HIV Infections
Intervention:  
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 26 Aug 2005 12:00:00 EDT

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: BMS-663068 400 mg;   Drug: BMS-663068 800 mg;   Drug: BMS-663068 600 mg;   Drug: BMS-663068 1200 mg;   Drug: Raltegravir 400 mg;   Drug: Tenofovir 300 mg;   Drug: Ritonavir 100 mg;   Drug: Atazanavir 300 mg
Sponsor:   ViiV Healthcare
Completed

Wed, 29 Jun 2011 12:00:00 EDT

Antiretroviral Therapy and Extreme Weight

Condition:   HIV Infection
Intervention:  
Sponsor:   Hopital Lariboisière
Completed

Wed, 06 Mar 2013 12:00:00 EST

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Condition:   HIV Infections
Interventions:   Drug: Fosamprenavir;   Drug: Saquinavir
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   Bristol-Myers Squibb;   GlaxoSmithKline;   Hoffmann-La Roche
Completed

Fri, 22 Jul 2005 12:00:00 EDT

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Didanosine;   Drug: Efavirenz;   Drug: Emtricitabine/Tenofovir disoproxil fumarate;   Drug: Lamivudine;   Drug: Lopinavir/Ritonavir;   Drug: Nevirapine;   Drug: Stavudine;   Drug: Tenofovir disoproxil fumarate;   Drug: Zidovudine/Lamivudine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Prevention Trials Network
Completed

Wed, 17 Dec 2003 12:00:00 EST

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition:   HIV Infections
Interventions:   Drug: Raltegravir (RAL);   Drug: Atazanavir (ATV);   Drug: Ritonavir (RTV);   Drug: Tenofovir (TDF);   Drug: Etravirine (ETV);   Drug: Darunavir (DRV);   Drug: Maraviroc (MVC);   Drug: Lopinavir/ritonavir (LPV/r)
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Wed, 16 Sep 2009 12:00:00 EDT

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Condition:   Human Immunodeficiency Virus Type 1
Interventions:   Drug: D/C/F/TAF;   Drug: Boosted Protease Inhibitor (bPI);   Drug: FTC/TDF
Sponsor:   Janssen R&D Ireland
Completed

Tue, 21 Oct 2014 12:00:00 EDT

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

Condition:   HIV-1 Infection
Interventions:   Drug: Doravirine, Tenofovir, Lamivudine;   Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor;   Drug: Baseline regimen of cobicistat-boosted elvitegravir;   Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor;   Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting

Tue, 24 Mar 2015 12:00:00 EDT

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Condition:   HIV Infections
Interventions:   Drug: Abacavir sulfate, Lamivudine and Zidovudine;   Drug: Atazanavir;   Drug: Lamivudine/Zidovudine;   Drug: Abacavir sulfate;   Drug: Efavirenz;   Drug: Nevirapine;   Drug: Lamivudine;   Drug: Stavudine;   Drug: Zidovudine;   Drug: Didanosine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Fri, 31 Aug 2001 12:00:00 EDT

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Conditions:   HIV;   HIV Infections
Interventions:   Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: EFV/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI
Sponsor:   Gilead Sciences
Completed

Thu, 21 Mar 2013 12:00:00 EDT

Comparative Tolerability of Protease Inhibitors

Condition:   HIV
Intervention:  
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 12 Oct 2011 12:00:00 EDT

Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects

Condition:   HIV
Interventions:   Procedure: Blood plasma collection;   Procedure: Cervical and Vaginal Biopsy;   Procedure: Colonoscopy with Ileal and Rectal Biopsy
Sponsor:   University of North Carolina, Chapel Hill
Terminated

Tue, 29 Dec 2015 12:00:00 EST

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Conditions:   HIV Infections;   Tuberculosis
Interventions:   Drug: Bictegravir (BIC);   Drug: Tenofovir alafenamide (TAF);   Drug: Cabotegravir (CAB);   Drug: Dolutegravir (DTG);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Lopinavir/ritonavir (LPV/r);   Drug: Cobicistat;   Drug: Ritonavir;   Drug: First-Line TB Treatment;   Drug: Second-Line TB Treatment;   Drug: Doravirine (DOR)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Mental Health (NIMH);   Gilead Sciences;   ViiV Healthcare;   Merck Sharp & Dohme Corp.
Recruiting

Wed, 19 Aug 2020 12:00:00 EDT

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

Condition:   HIV-1 Infection
Interventions:   Device: Nuvaring;   Drug: EFV;   Drug: ATV/r;   Drug: TDF;   Drug: NRTIs
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Fri, 19 Jul 2013 12:00:00 EDT

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Darunavir;   Drug: Efavirenz;   Drug: Nevirapine;   Drug: Ritonavir;   Drug: Tenofovir disoproxil fumarate;   Procedure: Pharmacokinetic Study
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Completed

Thu, 01 Dec 2005 12:00:00 EST

Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

Condition:   HIV
Interventions:   Drug: triple therapy;   Drug: dual therapy
Sponsors:   University Hospital, Tours;   HOSPITAL, ORLEANS;   Poitiers University Hospital;   Centre Hospitalier de La Rochelle;   HOSPITAL, SAINTES;   HOSPITAL, FOCH;   HOSPITAL, CAEN;   Henri Mondor University Hospital;   HOSPITAL, HOTEL DIEU;   HOSPITAL, CHARTRES;   HOSPITAL, SAINT LOUIS;   Tourcoing Hospital;   Central Hospital, NIORT;   Tenon Hospital, Paris;   Central Hospital, Nancy, France;   University Hospital, Rouen
Completed

Thu, 27 Nov 2014 12:00:00 EST

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

Conditions:   Human Immunodeficiency Virus;   Hepatitis B, Chronic;   Hepatitis C, Chronic
Intervention:   Drug: antiretroviral drugs
Sponsors:   Valme University Hospital;   Hospital Universitario Virgen de la Victoria;   Hospital Universitario Reina Sofia de Cordoba;   Hospital Torrecárdenas;   Hospital de la Línea de la Concepción;   Hospital Poniente;   Hospital Universitario Virgen Macarena;   Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Completed

Fri, 26 Jul 2013 12:00:00 EDT

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Condition:   Hepatitis C
Interventions:   Drug: Telaprevir;   Drug: Ribavirin;   Biological: Pegylated Interferon Alfa-2a;   Drug: Highly Active Antiretroviral Therapy (HAART)
Sponsor:   Vertex Pharmaceuticals Incorporated
Terminated

Tue, 08 Nov 2011 12:00:00 EST

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Conditions:   HIV;   Hepatitis C;   Liver Fibrosis
Interventions:   Drug: Raltegravir;   Drug: Ritonavir-boosted protease inhibitor
Sponsors:   McGill University Health Centre/Research Institute of the McGill University Health Centre;   Merck Sharp & Dohme Corp.;   CIHR Canadian HIV Trials Network
Completed

Mon, 01 Nov 2010 12:00:00 EDT

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

Conditions:   ADHD;   HIV
Intervention:  
Sponsor:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Completed

Tue, 02 Nov 2010 12:00:00 EDT

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Condition:   HIV Infections
Interventions:   Drug: EVG;   Drug: RTV;   Drug: ARV regimen
Sponsor:   Gilead Sciences
Completed

Thu, 08 Mar 2007 12:00:00 EST

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

Condition:   HIV Infections
Intervention:   Drug: Treatment discontinuation
Sponsors:   ANRS, Emerging Infectious Diseases;   IMEA Leon M'Ba Foundation;   Unit 1136 INSERM, Faculty of medecine, University Pierre and Marie Curie
Unknown status

Tue, 22 Aug 2017 12:00:00 EDT

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

Condition:   HIV Infection
Intervention:   Drug: Highly active antiretroviral therapy (HAART)
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Completed

Mon, 10 Aug 2009 12:00:00 EDT

MARCH Vascular Endothelium Substudy

Condition:   Cardiovascular Disease
Interventions:   Drug: NRTI + PI;   Drug: maraviroc + PI;   Drug: maraviroc + NRTI
Sponsor:   Kirby Institute
Completed

Thu, 26 Apr 2012 12:00:00 EDT

MARCH Renal Substudy

Conditions:   Proteinuria;   HIV
Interventions:   Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors;   Drug: Arm 2 boosted protease inhibitors and maraviroc;   Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
Sponsor:   Kirby Institute
Completed

Wed, 11 Jul 2012 12:00:00 EDT

4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients

Condition:   HIV-1 Infection
Intervention:   Drug: Four consecutive days on treatment and 3 days off
Sponsor:   ANRS, Emerging Infectious Diseases
Completed

Fri, 06 Jun 2014 12:00:00 EDT

MARCH Central Nervous System Substudy

Condition:   HIV-1 Infection
Interventions:   Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors;   Drug: Arm 2 Maraviroc and Protease Inhibitors;   Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
Sponsor:   Kirby Institute
Completed

Wed, 11 Jul 2012 12:00:00 EDT

Treatment De-Intensification and Residual HIV-1 in Youth

Conditions:   HIV-1;   HIV Infections
Intervention:   Other: Blood draw
Sponsors:   University of North Carolina, Chapel Hill;   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
Completed

Tue, 24 Mar 2009 12:00:00 EDT

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

Condition:   HIV-1
Interventions:   Drug: Etravirine (TMC125);   Drug: Optimized background regimen (OBR)
Sponsor:   Tibotec Pharmaceuticals, Ireland
Completed

Thu, 24 Apr 2008 12:00:00 EDT

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

Condition:   HIV Infections
Interventions:   Drug: DTG/3TC FDC;   Drug: CAR
Sponsors:   ViiV Healthcare;   GlaxoSmithKline;   PPD
Active, not recruiting

Tue, 16 Jul 2019 12:00:00 EDT

Telaprevir Open-Label Study in Co-Infected Patients

Condition:   Hepatitis C, Chronic
Intervention:   Drug: Telaprevir
Sponsor:   Janssen-Cilag International NV
Completed

Wed, 28 Dec 2011 12:00:00 EST

Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Conditions:   HIV-1-infection;   Antiretroviral Therapy
Interventions:   Drug: Continuation of boosted PI;   Drug: B/F/TAF
Sponsors:   Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic;   Brigham and Women's Hospital;   Harvard Medical School;   Analysis Group, Inc.;   Weill Medical College of Cornell University
Not yet recruiting

Tue, 17 Mar 2020 12:00:00 EDT

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

Conditions:   Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Interventions:   Drug: EVG;   Drug: Background regimen
Sponsor:   Gilead Sciences
Terminated

Thu, 15 Aug 2013 12:00:00 EDT

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Condition:   HIV Infection
Interventions:   Drug: Elvitegravir;   Drug: Raltegravir;   Drug: EVG placebo;   Drug: RAL placebo;   Drug: Background regimen
Sponsor:   Gilead Sciences
Completed

Wed, 02 Jul 2008 12:00:00 EDT


Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Conditions:   HIV;   HIV Infections
Interventions:   Drug: maraviroc;   Drug: control group
Sponsor:   Germans Trias i Pujol Hospital
Completed

Wed, 26 Aug 2009 12:00:00 EDT

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Condition:   Adverse Drug Reaction
Intervention:   Other: Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Sponsors:   Indiana University;   National Human Genome Research Institute (NHGRI)
Completed

Fri, 21 Nov 2014 12:00:00 EST

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Condition:   Human Immunodeficiency Virus
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Terminated

Wed, 20 Mar 2013 12:00:00 EDT

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

Condition:   HIV-1
Interventions:   Drug: F/TAF;   Drug: 3rd ARV agent;   Drug: Boosted PIs
Sponsor:   Gilead Sciences
Active, not recruiting

Thu, 06 Nov 2014 12:00:00 EST

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Conditions:   Hepatitis C, Chronic;   HIV Infection
Interventions:   Drug: Telaprevir;   Biological: pegIFN alfa-2a;   Drug: Ribavirin
Sponsors:   ANRS, Emerging Infectious Diseases;   Janssen-Cilag Ltd.
Completed

Mon, 11 Apr 2011 12:00:00 EDT


Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Condition:   HIV-1 Infection
Interventions:   Drug: E/C/F/TAF;   Drug: ABC/3TC;   Drug: Third Antiretroviral Agent
Sponsor:   Gilead Sciences
Completed

Tue, 17 Nov 2015 12:00:00 EST

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: PI;   Drug: RTV;   Drug: FTC/TDF;   Drug: Stribild
Sponsor:   Gilead Sciences
Completed

Mon, 21 Nov 2011 12:00:00 EST

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Condition:   HIV-1 Infection
Interventions:   Drug: FTC/RPV/TDF;   Drug: PI;   Drug: RTV;   Drug: NRTIs
Sponsor:   Gilead Sciences
Completed

Fri, 03 Dec 2010 12:00:00 EST

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Conditions:   Hepatitis C Virus Infection;   Human Immunodeficiency Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis and Non-cirrhotics
Interventions:   Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: ribavirin
Sponsor:   AbbVie
Completed

Wed, 11 Sep 2013 12:00:00 EDT

Kidney Stone Risk Factors in Patients Infected With HIV

Conditions:   Nephrolithiasis;   HIV
Intervention:  
Sponsor:   Corinne Isnard Bagnis
Unknown status

Fri, 29 May 2015 12:00:00 EDT

Kuwa Free! - Live Free!

Conditions:   HIV Infections;   Contraception;   Drug-drug Interaction
Interventions:   Drug: Cabotegravir/ Rilpivirine;   Drug: Etonogestrel (ETG) implant;   Drug: Intramuscular depo-medroxyprogesterone acetate (IM DMPA);   Drug: Levonorgestrel;   Drug: NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens
Sponsors:   University of Washington;   Moi Teaching and Referral Hospital;   Indiana University;   University of Nebraska;   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting

Thu, 16 Sep 2021 12:00:00 EDT

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Condition:   HIV-1 Infection
Interventions:   Drug: FTC/TDF;   Drug: F/TAF;   Drug: Allowed third antiretroviral agent;   Drug: FTC/TDF Placebo;   Drug: F/TAF Placebo
Sponsor:   Gilead Sciences
Completed

Thu, 24 Apr 2014 12:00:00 EDT

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Condition:   HIV-1 Infection
Interventions:   Drug: F/TAF;   Drug: ABC/3TC;   Drug: ABC/3TC Placebo;   Drug: F/TAF Placebo;   Drug: 3rd ARV agent
Sponsor:   Gilead Sciences
Completed

Thu, 11 Jun 2015 12:00:00 EDT

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

Conditions:   Infection, Human Immunodeficiency Virus;   HIV Infections
Interventions:   Drug: Cabotegravir (CAB) tablet;   Drug: Rilpivirine (RPV) tablet;   Drug: Cabotegravir - Injectable Suspension (CAB LA);   Drug: Rilpivirine - Injectable Suspension (RPV LA);   Drug: 2 NRTIs plus an INI, NNRTI, or PI
Sponsors:   ViiV Healthcare;   Janssen Pharmaceuticals;   GlaxoSmithKline
Active, not recruiting

Tue, 01 Nov 2016 12:00:00 EDT

Interaction With HIV Antiretroviral Agents

Condition:   HIV-DDI
Interventions:   Drug: Riociguat (Adempas, BAY 63-2521);   Drug: ATRIPLA;   Drug: COMPLERA;   Drug: STRIBILD;   Drug: TRIUMEQ;   Drug: Antiretroviral protease inhibitor
Sponsor:   Bayer
Completed

Tue, 22 Sep 2015 12:00:00 EDT

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Condition:   HIV-1 Infection
Interventions:   Drug: E/C/F/TAF;   Drug: TDF;   Drug: FTC;   Drug: FTC/TDF;   Drug: 3TC;   Drug: Third agent
Sponsor:   Gilead Sciences
Completed

Mon, 30 Nov 2015 12:00:00 EST